GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Jeong A Park(Memorial Sloan Kettering Cancer Center), Nai‐Kong V. Cheung(Memorial Sloan Kettering Cancer Center)
Cited by 86
Related Papers
Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
|Journal for ImmunoTherapy of Cancer|2021|47